---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007828"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:47:22.036285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene reports FY2025 net loss $26.2M; cash $5.2M; FDA type C meeting planned

## Summary
- Net loss of $26.2M ($2.65 per share) vs $39.4M ($5.67) in 2024.
- R&D expenses $14.0M, down from $20.1M; G&A $9.2M, down from $13.3M.
- Cash and equivalents $5.2M at Dec 31, 2025; expected runway to Q3 2026 after Jan 2026 offering.
- Oversubscribed $28M registered direct offering; initial tranche $6M priced above market.
- Type C FDA meeting before end of Mar 2026; NDA filing for CNM-Au8 in ALS by June 2026.

## SEC filing metadata
- accession: 0001437749-26-007828
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/0001437749-26-007828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/clnn20251022_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007828
- JSON: https://secwatch.observer/filing/0001437749-26-007828.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.